Acorah Software Products - Accounts Production 16.1.300 false true 31 October 2023 1 November 2022 false 1 November 2023 31 October 2024 31 October 2024 11644202 Dr M Akil Dr H M Akil iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11644202 2023-10-31 11644202 2024-10-31 11644202 2023-11-01 2024-10-31 11644202 frs-core:CurrentFinancialInstruments 2024-10-31 11644202 frs-core:ComputerEquipment 2024-10-31 11644202 frs-core:ComputerEquipment 2023-11-01 2024-10-31 11644202 frs-core:ComputerEquipment 2023-10-31 11644202 frs-core:RevaluationReserve 2023-11-01 2024-10-31 11644202 frs-core:RevaluationReserve 2023-10-31 11644202 frs-core:RevaluationReserve 2024-10-31 11644202 frs-core:ShareCapital 2024-10-31 11644202 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31 11644202 frs-bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 11644202 frs-bus:FilletedAccounts 2023-11-01 2024-10-31 11644202 frs-bus:SmallEntities 2023-11-01 2024-10-31 11644202 frs-bus:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 11644202 frs-bus:SmallCompaniesRegimeForAccounts 2023-11-01 2024-10-31 11644202 frs-core:DeferredTaxation 2023-11-01 2024-10-31 11644202 frs-core:DeferredTaxation 2023-10-31 11644202 frs-core:DeferredTaxation 2024-10-31 11644202 frs-core:UnlistedNon-exchangeTraded 2024-10-31 11644202 frs-core:UnlistedNon-exchangeTraded 2023-10-31 11644202 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2023-10-31 11644202 frs-core:RevaluationsIncreaseDecreaseInInvestments frs-core:UnlistedNon-exchangeTraded 2024-10-31 11644202 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-10-31 11644202 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2023-10-31 11644202 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-10-31 11644202 frs-bus:Director1 2023-11-01 2024-10-31 11644202 frs-bus:Director2 2023-11-01 2024-10-31 11644202 frs-countries:EnglandWales 2023-11-01 2024-10-31 11644202 2022-10-31 11644202 2023-10-31 11644202 2022-11-01 2023-10-31 11644202 frs-core:CurrentFinancialInstruments 2023-10-31 11644202 frs-core:RevaluationReserve 2023-10-31 11644202 frs-core:ShareCapital 2023-10-31 11644202 frs-core:RetainedEarningsAccumulatedLosses 2023-10-31
Registered number: 11644202
Peakside Medical Ltd
Unaudited Financial Statements
For The Year Ended 31 October 2024
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—5
Page 1
Balance Sheet
Registered number: 11644202
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 625 1,666
Investments 5 53,329 45,253
53,954 46,919
CURRENT ASSETS
Debtors 6 18,634 11,217
Cash at bank and in hand 452,412 345,070
471,046 356,287
Creditors: Amounts Falling Due Within One Year 7 (44,276 ) (40,610 )
NET CURRENT ASSETS (LIABILITIES) 426,770 315,677
TOTAL ASSETS LESS CURRENT LIABILITIES 480,724 362,596
PROVISIONS FOR LIABILITIES
Deferred Taxation 8 (119 ) (317 )
NET ASSETS 480,605 362,279
CAPITAL AND RESERVES
Called up share capital 10 40 40
Revaluation reserve 11 1,752 (5,426 )
Profit and Loss Account 478,813 367,665
SHAREHOLDERS' FUNDS 480,605 362,279
Page 1
Page 2
For the year ending 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Dr M Akil
Director
05/02/2025
The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Peakside Medical Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11644202 . The registered office is 174 Dore Road, Dore, Sheffield, S17 3HA.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Computer Equipment 25% straight line
2.4. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences.

3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2023: NIL)
1 -
4. Tangible Assets
Computer Equipment
£
Cost
As at 1 November 2023 4,360
As at 31 October 2024 4,360
Depreciation
As at 1 November 2023 2,694
Provided during the period 1,041
As at 31 October 2024 3,735
Net Book Value
As at 31 October 2024 625
As at 1 November 2023 1,666
Page 3
Page 4
5. Investments
Unlisted
£
Cost
As at 1 November 2023 45,253
Revaluations 8,076
As at 31 October 2024 53,329
Provision
As at 1 November 2023 -
As at 31 October 2024 -
Net Book Value
As at 31 October 2024 53,329
As at 1 November 2023 45,253
6. Debtors
2024 2023
£ £
Due within one year
Trade debtors 18,634 11,217
7. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Corporation tax 35,863 26,451
Accruals and deferred income 1,626 1,396
Directors' loan accounts 6,787 12,763
44,276 40,610
8. Deferred Taxation
The provision for deferred tax is made up as follows:
2024 2023
£ £
Other timing differences 119 317
9. Provisions for Liabilities
Deferred Tax Total
£ £
As at 1 November 2023 317 317
Deferred taxation (198 ) (198 )
Balance at 31 October 2024 119 119
Provision is made for the potential charge to tax that would arise should the company dispose of its fixed assets at the stated net book value to the extent that this is in excess of the tax written down value.
Page 4
Page 5
10. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 40 40
11. Reserves
Revaluation Reserve
£
As at 1 November 2023 (5,426 )
Transfer to profit and loss 7,178
As at 31 October 2024 1,752
Page 5